NCT01281917 - Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

June 30, 2014

Conditions

Non-Hodgkins Lymphoma

Interventions

DRUG

Velcade

Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22)

DRUG

Temsirolimus

Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)

Trial Locations (18)

53066

Aurora Medical Center in Summit, Summit

53081

Aurora Sheboygan Memorial Medical Center, Sheboygan

53188

Waukesha Memorial Hospital, Waukesha

53211

Columbia St Mary's, Inc, Milwaukee

53226

Medical College of Wisconsin, Milwaukee

Aurora Health Care Metro, Inc., Wauwatosa

53715

UW Health Oncology- 1 S Park, Madison

53792

University Of Wisconsin Cancer Center, Madison

54143

Aurora Baycare Medical Center-GreenBay, Green Bay

54241

Aurora Medical Center in Two Rivers, Two Rivers

54301

St Vincent Regional Cancer Center CCOP, Green Bay

54313

Bellin Memorial Hospital, Inc, Green Bay

54401

Aspirus Wausau Hospital, Wausau

54449

Marshfield Clinic, Marshfield

54494

UW Cancer Center-Riverview, Wisconsin Rapids

54601

Gunderson Lutheran Health System, La Crosse

57701

Rapid City Regional Hospital John T. Vucurevich Cancer Care Institute, Rapid City

Unknown

Aurora BayCare Medical Center, Marinette